In addition to the substantial clinical burden that is tied to diabetes in US, the annual economic burden that is associated with disease management jumps from $18 billion to $232 billion between the transition of pre-diabetes to full-fledged diabetes. In an effort to prevent that shift to diabetes, mitigate the development of detrimental comorbidities, and to avoid downstream consequences such as end-stage organ damage, the panelists acknowledged that it is critical to diagnose and treat patients earlier and more aggressively. Although patients will present with varying stages of disease upon initial diagnosis, there is optimism that opportunities can be created and seized to better patient outcomes, improve quality of life, and reduce the managed care burden.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Impact of Hospital-Physician Integration on Medicare Patient Mix
April 11th 2025This study found no evidence that hospital employment of physicians resulted in physicians treating sicker patients, undercutting claims that hospital-employed physicians serve a higher-acuity patient mix.
Read More